Tacquet A
Nouv Presse Med. 1975 Dec 31;4(46 Suppl):3294-6.
This double-blind clinical study was carried out in order to compare the therapeutic activity of propranolol, and a new beta-adrenergic blocker, acebutolol, in essential hypertension. The hypotensive activity of acebutolol was confirmed when a dosage of 600 mg/day was used, with en absence of side effects.